Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice

PLoS ONE

Volumn 4, Issue 12, 2009, Pages

  Nierkens, Stefan ^a   den Brok, Martijn H ^a   Roelofsen, Thijs ^a   Wagenaars, Jori A L ^a   Figdor, Carl G ^a   Ruers, Theo J ^b   Adema, Gosse J ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9 AGONIST; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL ACTIVATION; CONTROLLED STUDY; CRYOSURGERY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG TREATMENT FAILURE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; NONHUMAN; PROTEIN SECRETION; SOLID TUMOR; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CROSS-PRIMING; DENDRITIC CELLS; DRUG ADMINISTRATION ROUTES; IMMUNITY; IMMUNOTHERAPY, ADOPTIVE; INJECTIONS; LYMPH NODES; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTOR 9; TREATMENT OUTCOME;

ANIMALIA; MUS;

EID: 77949512384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0008368     Document Type: Article

References (39)

1. Mulier S, Ni Y, Jamart J, Michel L, Marchal G, et al. (2008) Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Ann Surg Oncol 15: 144-157.
2. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, et al. (2007) Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 13: 1050-1059.
3. Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, et al. (2003) Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171: 5940-5947.
4. den Brok MH, Nierkens S, Figdor CG, Ruers TJ, Adema GJ (2005) Dendritic cells: tools and targets for antitumor vaccination. Expert Rev Vaccines 4: 699-710.
5. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG (2003) Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 170: 178-179.
6. den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, et al. (2004) In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 64: 4024-4029.
7. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, et al. (2006) Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer 95: 896-905.
8. Krieg AM (2002) CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760.
9. Rutz M, Metzger J, Gellert T, Luppa P, Lipford GB, et al. (2004) Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur J Immunol 34: 2541-2550.
10. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, et al. (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5: 190-198.
11. Baines J, Celis E (2003) Immune-mediated tumor regression induced by CpG- containing oligodeoxynucleotides. Clin Cancer Res 9: 2693-2700.
12. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, et al. (2002) Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. J Immunol 169: 3892-3899.
13. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, et al. (2001) Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci U S A 98: 9237-9242.
14. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, et al. (2002) Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeox- ynucleotides. J Immunol 168: 4531-4537.
15. Hoene V, Peiser M, Wanner R (2006) Human monocyte-derived dendritic cells express TLR9 and react directly to the CpG-A oligonucleotide D19. J Leukoc Biol 80: 1328-1336.
16. Kuwajima S, Sato T, Ishida K, Tada H, Tezuka H, et al. (2006) Interleukin 15- dependent crosstalk between conventional and plasmacytoid dendritic cells is essential for CpG-induced immune activation. Nat Immunol 7: 740-746.
17. Gerosa F, Gobbi A, Zorzi P, Burg S, Briere F, et al. (2005) The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol 174: 727-734.
18. Badovinac VP, Messingham KA, Jabbari A, Haring JS, Harty JT (2005) Accelerated CD8(+) T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 11: 748-756.
19. Davila E, Kennedy R, Celis E (2003) Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63: 3281-3288.
20. Milas L, Mason KA, Ariga H, Hunter N, Neal R, et al. (2004) CpG oligodeoxynucleotide enhances tumor response to radiation. Cancer Res 64: 5074-5077.
21. Nierkens S, den Brok MH, Sutmuller RP, Grauer OM, Bennink E, et al. (2008) In vivo colocalization of antigen and CpG within dendritic cells is associated with the efficacy of cancer immunotherapy. Cancer Res 68: 5390-5396.
22. Falo LD Jr, Kovacsovics-Bankowski M, Thompson K, Rock KL (1995) Targeting antigen into the phagocytic pathway in vivo induces protective tumor immunity. Nat Med 1: 649-653.
23. Burgdorf S, Lukacs-Kornek V, Kurts C (2006) The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol 176: 6770-6776.
24. Rock KL, Shen L (2005) Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 207: 166-183.
25. Furumoto K, Soares L, Engleman EG, Merad M (2004) Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest 113: 774-783.
26. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Toonen LW, et al. (2006) Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 66: 7285-7292.
27. Huang A, McCall JM, Weston MD, Mathur P, Quinn H, et al. (2002) Phase I study of percutaneous cryotherapy for colorectal liver metastasis. Br J Surg 89: 303-310.
28. Schmidt C (2007) Clinical setbacks for toll-like receptor 9 agonists in cancer. Nat Biotechnol 25: 825-826.
29. Fallarino F, Puccetti P (2006) Toll-like receptor 9-mediated induction of the immunosuppressive pathway of tryptophan catabolism. Eur J Immunol 36: 8-11.
30. Ninalga C, Loskog A, Klevenfeldt M, Essand M, Totterman TH (2005) CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer. J Immunother 28: 20-27.
31. von Beust BR, Johansen P, Smith KA, Bot A, Storni T, et al. (2005) Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 35: 1869-1876.
32. Wingender G, Garbi N, Schumak B, Jungerkes F, Endl E, et al. (2006) Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. Eur J Immunol 36: 12-20.
33. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, et al. (2005) Cutting Edge: CpG Oligonucleotides Induce Splenic CD19+ Dendritic Cells to Acquire Potent Indoleamine 2,3-Dioxygenase-Dependent T Cell Regulatory Functions via IFN Type 1 Signaling. J Immunol 175: 5601-5605.
34. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, et al. (2004) Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10: 187-192.
35. Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL (2004) Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother (1997) 27: 460-471.
36. Allan RS, Waithman J, Bedoui S, Jones CM, Villadangos JA, et al. (2006) Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25: 153-162.
37. van Maren WW, Jacobs JF, de Vries IJ, Nierkens S, Adema GJ (2008) Toll-like receptor signalling on Tregs: to suppress or not to suppress? Immunology 124: 445-452.
38. Murad YM, Clay TM, Lyerly HK, Morse MA (2007) CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy. Expert Opin Biol Ther 7: 1257-1266.
39. Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, et al. (2004) CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 24: 693-701.